News & Updates

Immunosuppression with prednisone plus either adalimumab or cyclosporine is effective in improving alopecia, but neither treatment does not provide any significant impact on the presence of vitiligo or poliosis in patients with Vogt-Koyanagi-Harada (VKH) disease at 6 months, reports a study.

Adding adjuvant chemotherapy to hormonotherapy does not appear to improve survival outcomes in older women with high-risk estrogen receptor (ER)-positive, HER2-negative breast cancer and is even associated with more adverse events, as shown in a phase III study.

Treatment with daridorexant improved sleep outcomes and daytime functioning in women with insomnia disorder during the menopausal transition, according to a study presented at EAN 2025.

Treatment with steroidal mineralocorticoid receptor antagonists does not appear to provide significant protection against cardiovascular mortality in patients undergoing dialysis, as shown in a systematic review and meta-analysis.

The use of rituximab falls short of demonstrating superiority over a conventional remission induction strategy in patients diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA), reveals a study.

In Asian patients with severe chronic rhinosinusitis with nasal polyps who are receiving daily intranasal corticosteroid, add-on treatment with the novel monoclonal antibody stapokibart helps shrink polyp size and bring down the severity of symptoms, as shown in the phase III CROWNS-2 study conducted in China.

Treatment with canagliflozin significantly reduces haemoglobin A1c (HbA1c) in children and adolescents with type 2 diabetes mellitus (T2DM), with a safety profile comparable to that seen in adults, results of a phase III trial have shown.

In patients with large chronic wounds secondary to recessive dystrophic epidermolysis bullosa (RDEB), treatment with prademagene zamikeracel helps with wound healing and pain while being well tolerated, according to a phase III study.

A recent study in Singapore has found a lack of easily accessible detailed information on light protection in package inserts (PIs) of light-sensitive injectable drugs beyond the phrase “Protect from light.”

Combination treatment with sacubitril and valsartan demonstrates greater efficacy than standard therapy in achieving blood pressure (BP) control and BP reduction in Afro-descendant patients with resistant hypertension, reports a study.